Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
(4) - EconoTimes)
DUBLIN, IRELAND, May 04, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2018 of inducement restricted stock units for an aggregate of 228,305 ordinary shares to 30 new employees.
Certain of the restricted stock units vest over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, and certain of the restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]
